Indications |
Intravenous As an anticoagulant in percutaneous coronary intervention Adult: 750 mcg/kg by intravenous inj followed by an infusion of 1.75 mg/kg/hr during procedure and up to 4 hours postprocedure. If needed, may continue infusion at 0.2 mg/kg/hr for up to 20 hours.
|
||||||||
Contraindications |
Active major bleeding. CrCl <30 ml/min and dialysis-dependent patients. | ||||||||
Warnings / Precautions |
Patients at risk of serious bleeding, recent major surgery or puncture of large vessels or organ biopsy. Hepatic or renal impairment. | ||||||||
Adverse Reactions |
Bleeding, hypersensitivity reactions. Hypertension, hypotension, bradycardia, nausea, vomiting, dyspepsia, urinary retention, back pain, headache, injection site pain & anxiety. Potentially Fatal: Severe anaphylactic reactions which may lead to death. (See lit) |
||||||||
Drug Interactions |
May increase risk of bleeding when used with thrombolytics, oral anticoagulants or drugs that affect platelet function. See Below for More bivalirudin Drug Interactions |
||||||||
Mechanism of Actions |
Bivalirudin is an analogue of the peptide hirudin. It is a specific and reversible direct thrombin inhibitor thats works by binding to the catalytic and anionic exosite of circulating and clot-bound thrombin. It is used as an anticoagulant in percutaneous coronary intervention. Distribution: Does not bind to plasma proteins. Metabolism: Partly metabolised by the kidneys. Excretion: Partially cleared renally and proteolytic cleavage. Elimination half-life (normal renal function): 25 minutes. |
||||||||
Storage Conditions |
Intravenous: Store unopened vials at 15-30°C. Store reconstituted vials at 2-8°C. | ||||||||
ATC Classification |
B01AE06 - bivalirudin ; Belongs to the class of direct thrombin inhibitors. Used in the treatment of thrombosis. | ||||||||
Storage |
Intravenous: Store unopened vials at 15-30°C. Store reconstituted vials at 2-8°C. | ||||||||
Available As |
|
Bivalirudin
Post Review about Bivalirudin Click here to cancel reply.
Bivalirudin Containing Brands
Bivalirudin is used in following diseases
Drug - Drug Interactions of Bivalirudin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.